Literature DB >> 1733349

A flow cytometric, clinical, and histological study of stromal neoplasms of the gastrointestinal tract.

P N Cooper1, P Quirke, G J Hardy, M F Dixon.   

Abstract

Histological sections of 102 stromal neoplasms of the gastrointestinal tract occurring in 100 patients have been assessed for 23 clinical and histological parameters and the corresponding paraffin embedded (archival) material processed for flow cytometry. Where possible, information as to clinical presentation and survival was obtained. The only absolute criterion for malignancy was the presence of spread of tumour beyond the organ of origin at the time of diagnosis. Of the remaining tumours (i.e., tumours locally confined at diagnosis), those found incidentally at operation and those of a small size (less than 60 mm diameter) behaved in a generally benign fashion. Of the histological parameters, six correlated with malignant behaviour: high mitotic count, high cellularity, marked nuclear pleomorphism, rounded as opposed to spindle cell shape, bizarre mitoses, and vascular invasion. The presence of DNA aneuploidy as shown by flow cytometry correlated strongly with a poor prognosis (p less than 0.0005). Tumours with a high mitotic count [greater than 9 per 10 high-power fields (hpf) (1.59 mm2)] behaved in an almost uniformly malignant fashion. Those with a low mitotic count [less than 3/10hpf (1.59 mm2)], behaved in a benign fashion apart from one case where no mitoses were discernible yet the tumour metastasised and killed the patient. The intermediate group of tumours (3-9 mitoses per 10 hpf inclusive) were difficult to predict, although the majority behaved in a malignant fashion. Within this group the presence of DNA aneuploidy appeared most useful in predicting prognosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733349     DOI: 10.1097/00000478-199202000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  Gastric stromal tumours: a practical approach.

Authors:  N Mihssin; K Moorthy; A Sengupta; P W Houghton
Journal:  Ann R Coll Surg Engl       Date:  2000-11       Impact factor: 1.891

Review 2.  Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib.

Authors:  Chandu M V de Silva; Robin Reid
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

Review 3.  The histopathological differential diagnosis of gastrointestinal stromal tumours.

Authors:  J F Graadt van Roggen; M L van Velthuysen; P C Hogendoorn
Journal:  J Clin Pathol       Date:  2001-02       Impact factor: 3.411

4.  DNA ploidy and c-Kit mutation in gastrointestinal stromal tumors.

Authors:  Ju Han Lee; Xianglan Zhang; Woon Yong Jung; Yang Seok Chae; Jong Jae Park; Insun Kim
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

5.  Frequent occurrence of low grade cases among metastatic gastrointestinal stromal tumours.

Authors:  T Tornóczky; E Kövér; L Pajor
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

Review 6.  Multidisciplinary treatment of gastrointestinal stromal tumors.

Authors:  T Peter Kingham; Ronald P DeMatteo
Journal:  Surg Clin North Am       Date:  2009-02       Impact factor: 2.741

7.  Multiple benign stromal cell tumours of the small bowel.

Authors:  J A Gall; R Chetty; A J Kemp; J C Penfold
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

Review 8.  Gastrointestinal stromal tumors: key to diagnosis and choice of therapy.

Authors:  Piotr Rutkowski; Maria Debiec-Rychter; Wlodzimierz Ruka
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Stromal tumours of the gastrointestinal tract: a clinicopathological and ploidy analysis of 33 cases.

Authors:  E Lerma; E Oliva; D Tugués; J Prat
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

Review 10.  Management of resectable gastrointestinal stromal tumor.

Authors:  Umer I Chaudhry; Ronald P DeMatteo
Journal:  Hematol Oncol Clin North Am       Date:  2009-02       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.